A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia
Phase 2
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-jRCT2080222170
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients (over 20 years of age and under 80 years of age) with Hypercholesterolemia
Patient who is on a stable diet and on a stable daily dose of statin
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie LY3015014's efficacy in primary hypercholesterolemia compared to PCSK9 inhibitors?
How does LY3015014's dose-response profile compare to standard-of-care lipid-lowering therapies in familial hypercholesterolemia patients?
Which biomarkers correlate with LDL-C reduction in Eli Lilly's Phase 2 LY3015014 trial for hypercholesterolemia?
What adverse event patterns emerged in LY3015014 trials versus other monoclonal antibodies targeting lipid metabolism?
Are there synergistic combination strategies involving LY3015014 and bempedoic acid for refractory hypercholesterolemia?